We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Tamoxifen (Nolvadex)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Tamoxifen (Nolvadex) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1998–2019 with a typical study size of 176 participants.
Based on 8 studies · 3 meta-analyses · 3 RCTs · 13,709 total participants
Confidence
HighBy outcome
Tamoxifen (Nolvadex) has an evidence score of 5.2/10 — emerging evidence based on 8 indexed studies, including 4 meta-analyses. A selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug. Representative study: PMID 21802721.
Testosterone (TRT)
Mostly mechanism / observationalThe primary male androgen and an FDA-approved prescription drug for diagnosed male hypogonadism — and a Schedule III CONTROLLED SUBSTANCE. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only; non-medical, supraphysiologic, and 'anti-aging' use is illegal and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
Notable regimens that report including Tamoxifen (Nolvadex) — documented, not endorsed.
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tamoxifen citrate (Nolvadex) — the prototype triphenylethylene SERM
A selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.
Tamoxifen has some of the strongest evidence in all of medicine for its APPROVED use — EBCTCG meta-analysis shows ~5 years of adjuvant tamoxifen roughly halves breast-cancer recurrence and cuts breast-cancer death by about a third in ER-positive disease, and NSABP P-1 proves it prevents breast cancer in high-risk women. For the off-label MALE uses this collection cares about, the evidence is genuine but lower-tier: multiple RCTs and a systematic review support tamoxifen for preventing/treating gynecomastia (especially antiandrogen-induced), and class meta-analyses show it raises FSH/testosterone, sperm parameters and pregnancy rate in idiopathic male infertility — but PCT use is essentially unstudied, and the male data are largely surrogate-based and off-label. The score is held in the emerging band by the MANDATORY safety counterweight: tamoxifen significantly increases endometrial cancer (~2.5x) and venous thromboembolism (DVT, pulmonary embolism, stroke) in the same pivotal trials, plus ocular risk. Strong for breast cancer, effective for gynecomastia, but off-label male hormonal use carries real, documented risks. NOT a longevity drug.
Tamoxifen citrate (Nolvadex, Soltamox) is the prototype selective estrogen receptor modulator (SERM) — a triphenylethylene that acts as an estrogen antagonist in some tissues (notably breast) and a partial agonist in others (bone, endometrium, the clotting system). It has been a cornerstone of oncology for decades and is one of the best-evidenced drugs in all of medicine for its approved indication. In estrogen-receptor (ER)-positive breast cancer, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) patient-level meta-analysis of randomized trials showed that about five years of adjuvant tamoxifen roughly halves the recurrence rate over the first decade and reduces breast-cancer mortality by about a third sustained across 15 years — a survival benefit driven entirely by ER-positive disease (tamoxifen does essentially nothing in ER-negative tumors). The NSABP P-1 Breast Cancer Prevention Trial (13,388 high-risk women) then showed tamoxifen cuts the incidence of invasive breast cancer by 49% in women who do not yet have the disease, establishing it as a chemoprevention agent. These are large, randomized, mortality-relevant outcomes in the approved population — the strong end of the evidence.
Men use tamoxifen off-label for two mechanistically distinct reasons, both tied to its estrogen antagonism. First, in the breast itself: because gynecomastia (male breast tissue growth) is estrogen-driven, tamoxifen blocks the estrogen receptor in breast tissue and prevents or shrinks it. This is the best-evidenced off-label male use — multiple randomized trials show tamoxifen markedly reduces gynecomastia and breast pain induced by antiandrogen (bicalutamide) therapy for prostate cancer, with prophylactic dosing (started alongside the antiandrogen) outperforming reactive treatment, and a systematic review confirms it as the leading pharmacologic option in that setting; smaller series show benefit in idiopathic and persistent pubertal gynecomastia too. Second, at the brain: tamoxifen antagonizes estrogen receptors at the hypothalamus and pituitary, so the negative feedback that estrogen normally exerts on gonadotropin-releasing hormone is released. The pituitary then secretes more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which raises endogenous testosterone and supports spermatogenesis. This is the rationale behind tamoxifen's appearance in idiopathic-male-infertility regimens — meta-analyses of the estrogen-antagonist class (clomiphene/tamoxifen) report increased sperm concentration, raised FSH and testosterone, and a higher spontaneous pregnancy rate — and behind its heavy off-label use in bodybuilding 'post-cycle therapy' (PCT), where it is taken to restart the suppressed hypothalamic-pituitary-testicular axis after an anabolic-steroid cycle (a use that has essentially no controlled-trial evidence at all).
The honest appraisal hinges on the safety profile, which is the entire counterweight to the efficacy. Tamoxifen's tissue-selective estrogen agonism is a double-edged sword: in the endometrium it is estrogenic, and the P-1 trial showed roughly a 2.5-fold increase in endometrial cancer; in the clotting system it raises the risk of venous thromboembolism — deep-vein thrombosis, pulmonary embolism, and stroke — events that were significantly elevated in both the prevention and adjuvant trials, especially in women over 50. It can also cause visual/ocular effects (retinopathy, corneal/lens changes, reduced visual acuity), hot flushes, and mood changes. These are not theoretical: the endometrial-cancer and thromboembolic signals are documented in the same pivotal randomized trials that prove its benefit. For a man taking it off-label for gynecomastia, fertility, or PCT — typically without the oncologic indication that justifies accepting those risks — the clot and (where relevant) endometrial concerns, plus the ocular risk, are the mandatory part of the conversation. Tamoxifen is a genuinely powerful, well-proven drug for ER-positive breast cancer and an effective, RCT-supported treatment for gynecomastia; its hormonal/PCT use in men is common and mechanistically coherent but largely surrogate-based and off-label, and it carries real venous-thromboembolic and endometrial risk. It is a prescription oncology/hormonal drug, not a dietary supplement and not a longevity agent.
Tamoxifen competitively blocks the estrogen receptor in breast tissue. In ER-positive breast cancer this starves estrogen-driven tumor growth; in men it prevents or shrinks estrogen-driven gynecomastia — the best-evidenced off-label male use.
By antagonizing estrogen receptors at the hypothalamus and pituitary, tamoxifen releases the negative feedback estrogen exerts on gonadotropin-releasing hormone. The pituitary secretes more LH and FSH, raising endogenous testosterone and supporting spermatogenesis — the basis for male-infertility and PCT use.
As a SERM, tamoxifen is a partial estrogen AGONIST in bone (protective), but also in the endometrium (endometrial-cancer risk) and the clotting system (venous-thromboembolism risk). This tissue selectivity is exactly why the same drug protects against breast cancer yet raises uterine-cancer and clot risk.
How Tamoxifen (Nolvadex) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.
Can be taken without food
| Form | Type |
|---|---|
| 💊Tamoxifen citrate tablets (approved for breast cancer; off-label in men) | Recommended |
| 💊Raloxifene (a SERM with less endometrial-agonist risk; used for breast-cancer prevention and studied in pubertal gynecomastia) | Alternative |
| 💊Aromatase inhibitors (anastrozole; lower the estrogen itself rather than blocking the receptor — but anastrozole underperformed tamoxifen for antiandrogen gynecomastia) | Alternative |
| 💊Clomiphene / enclomiphene (SERMs used off-label to raise male testosterone via LH/FSH while preserving fertility) | Alternative |
Tamoxifen is the prototype SERM — an estrogen antagonist in breast and at the hypothalamus, but a partial agonist in endometrium and the clotting system, which is the source of its main risks.
Compare Tamoxifen (Nolvadex) vs Raloxifene (Evista) →Minimum: 6 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Oncology use is a fixed 20 mg/day for 5-10 years; off-label male use is once-daily and clinician-directed, titrated to response (breast symptoms, or testosterone and LH/FSH). Not a fixed supplement schedule.
Dose-response data unavailable. The current published research for Tamoxifen (Nolvadex) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In ER-positive breast cancer, ~5 years of adjuvant tamoxifen roughly halves recurrence and cuts breast-cancer death by about a third; in high-risk women it prevents breast cancer. The approved, strongly-evidenced indication.
Tamoxifen blocks estrogen in breast tissue, reducing male breast growth and pain — well-supported by RCTs during antiandrogen therapy, with prophylaxis outperforming reactive treatment, and helpful in idiopathic/pubertal cases.
By blocking estrogen feedback at the hypothalamus, tamoxifen raises gonadotropins and endogenous testosterone and improves sperm parameters — the rationale for male-infertility regimens and bodybuilding post-cycle therapy.
Tamoxifen's estrogen-agonist effects raise the risk of endometrial cancer (~2.5x) and venous thromboembolism — deep-vein thrombosis, pulmonary embolism, and stroke — documented in the same pivotal trials. The mandatory honest limit.
Tamoxifen can cause retinopathy, corneal/lens (cataract) changes, and reduced visual acuity, particularly with prolonged use. Report new visual symptoms promptly.
This is the best-evidenced off-label male use — RCTs show tamoxifen prevents and treats gynecomastia, with prophylaxis (started alongside an antiandrogen) more effective than reactive dosing. Off-label; weigh the clot/ocular risks and use under medical supervision.
Tamoxifen raises LH/FSH and endogenous testosterone and improves sperm parameters in idiopathic infertility, but PCT use specifically has essentially no controlled-trial evidence. Off-label and surrogate-based; the venous-thromboembolism risk still applies.
Higher-risk — tamoxifen raises venous-thromboembolism risk and interacts with warfarin. Often contraindicated; discuss before use.
Tamoxifen can cause ocular changes; consider baseline and periodic eye exams and report visual changes.
Tamoxifen can potentiate anticoagulant effect and raise bleeding risk; co-use is contraindicated in the prevention setting and requires close INR monitoring otherwise.
Tamoxifen is converted by CYP2D6 to its active metabolite endoxifen; strong CYP2D6 inhibitors can lower endoxifen levels and may reduce efficacy.
Tip: A documented, dose-relevant risk elevated in the pivotal trials (more in those over 50). Seek urgent care for leg swelling/pain, chest pain, breathlessness, or stroke symptoms; avoid with prior clot history.
Tip: Tamoxifen roughly doubled endometrial-cancer risk in P-1 (~2.5x); report abnormal uterine bleeding promptly. Not relevant to male use, but central to the drug's risk profile.
Tip: Report new visual symptoms; periodic eye exams are reasonable with prolonged use. Often partially reversible on stopping.
Tip: A common, usually tolerable SERM effect from estrogen antagonism.
The commonly studied dose of Tamoxifen (Nolvadex) is Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Tamoxifen (Nolvadex) — consistent daily use matters more than the time of day. Taken as an oral tablet (or oral solution) once daily, with or without food.
Tamoxifen (Nolvadex) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are venous thromboembolism (DVT, pulmonary embolism, stroke), endometrial cancer / uterine changes (women), visual / ocular effects (retinopathy, cataract, reduced acuity). Use caution if any of these apply to you: History of venous thromboembolism (deep-vein thrombosis or pulmonary embolism) or stroke — tamoxifen raises clot risk; Concurrent warfarin / anticoagulant therapy in the prevention setting (per label); Pregnancy and breastfeeding (can harm the fetus).
Exemestane
Mostly mechanism / observationalA steroidal, irreversible ('suicide') aromatase inhibitor (Aromasin) approved for hormone-receptor-positive breast cancer, where its evidence is strong (the IES switch trial, MAP.3 prevention, and head-to-head with anastrozole in MA.27). It is the steroidal counterpart to anastrozole and letrozole, and because its metabolite is mildly androgenic it is sometimes claimed to spare bone — but the trials show it still lowers bone-mineral density and raises fracture risk. Used off-label in men to lower estradiol and raise testosterone, a small crossover RCT confirms it does shift the hormones, but estrogen is required for the male skeleton and lipids. A prescription drug, not a supplement, and NOT a longevity drug.
Overlapping or opposing effects on the estrogen axis; combinations (common in TRT/PCT and oncology) can produce unpredictable estradiol, lipid, and bone effects and are often not well validated.
Tip: Monitor and discuss with the prescribing clinician.